Center of Research on Obesity and Cardiovascular Disease

肥胖与心血管疾病研究中心

• 批准号: 10458562
• 负责人: Lisa A Cassis
• 金额: $ 114.75万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10458562
• 关键词: Adipose tissue; Advisory Committees; Aging; Alzheimer' s Disease; Area; Award; Basic Science; Body Composition; Cardiovascular Diseases; Cardiovascular system; Center for Translational Science Activities; Centers of Research Excellence; Chronic Disease; Clinical Research; Clinical Sciences; Core Facility; Death Rate; Development; Diabetes Mellitus; Disease; Equipment; Etiology; Evaluation; Extramural Activities; Fostering; Funding; Gills; Goals; Growth; High Prevalence; Hypertension; Infrastructure; Institutes; Institution; Kentucky; Limb structure; Link; Lipids; Malignant Neoplasms; Mass Spectrum Analysis; Mentors; Morphology; Mus; Neurodegenerative Disorders; Neurosciences; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Pathology; Phase; Physicians; Pilot Projects; Prevalence; Publications; Publishing; Request for Applications; Research; Research Infrastructure; Research Personnel; Research Support; Risk; Risk Factors; Scientist; Services; Strategic Planning; System; Technology; Tissues; Translating; Translational Research; United States National Institutes of Health; Universities; cancer research center director; cardiovascular risk factor; clinical care; clinical center; comorbidity; dietary; energy balance; experience; health disparity; human disease; improved; lipidomics; obesity development; programs; research facility; small molecule; success; targeted treatment; therapy development; voucher

Phase III of the Center for Biomedical Research Excellence (COBRE) on Obesity and Cardiovascular Diseases (COCVD) will further develop and expand upon obesity as an underlying risk factor for the development of cardiovascular diseases, type 2 diabetes, cancer and neurodegenerative diseases. Each of these diseases are rampant in Kentucky, and obesity has been identified as a contributing risk factor for each condition. For Phase III of the COCVD, we will transition the research core facilities developed during Phase I and II of this program to independence. We will also support pilot project studies that include obesity as a risk factor for disease development. We have experienced considerable success, having supported 23 junior investigators and 21 pilot project investigators who generated $52 million in extramural funding and published more than 500 scholarly publications. Collectively, our team has published more than 280 scholarly articles that directly cite COCVD support. We developed an analytical core that provides services in lipidomics and other small molecules, a pathology core that provides specialized services to quantify adipose and other tissue morphology, and an energy balance and body composition core that is not duplicated in capacity across the institution or the Commonwealth. During Phase III of the COCVD, we will transition each core to self- sustaining capacity and upgrade core equipment and use by continuing to provide high quality specialized services, and by expanding core capabilities through provision of additional services that relate obesity to other diseases (e.g., cancer). Transition to independence of COCVD cores will be facilitated by use of a voucher system to promote core use. We will also continue our strong tradition of pilot project funding, which will be expanded to include studies that focus on obesity as an underlying risk factor for not only cardiovascular diseases, but also type 2 diabetes, cancer and neurodegenerative diseases. These areas have been designated as areas of strength across the institution (as each disease is a health disparity experienced by Kentuckians), and are designated for growth within a new research facility that will focus on Kentucky's health disparities. The Administrative Core will oversee all administrative functions of the COCVD and in conjunction with the Program Coordinator and the Scientific Internal Advisory Committee will serve as the operational limb of the Center. An External Advisory Committee, composed of experts in related fields, will provide ongoing assessment and evaluation of the Center. Institutional commitment continues to be outstanding and is supplemented by strong evidence of programmatic growth of direct relevance to this Phase III COCVD.

卓越生物医学研究中心（COBRE）关于肥胖和心血管疾病的第三期研究

项目成果

Monosomy X in Female Mice Influences the Regional Formation and Augments the Severity of Angiotensin II-Induced Aortopathies.

雌性小鼠的单肌X会影响区域形成，并增加血管紧张素II诱导的主动脉病的严重程度。

• DOI: 10.1161/atvbaha.120.314407
• 发表时间: 2021-01
• 期刊: Arteriosclerosis, thrombosis, and vascular biology
• 作者: AlSiraj Y;Thatcher SE;Blalock E;Saintilnord WN;Daugherty A;Lu HS;Luo W;Shen YH;LeMaire SA;Arnold AP;Cassis LA
• 通讯作者: Cassis LA

A Novel Role of Claudin-5 in Prevention of Mitochondrial Fission Against Ischemic/Hypoxic Stress in Cardiomyocytes.

• DOI: 10.1016/j.cjca.2021.03.021
• 发表时间: 2021-10
• 期刊: The Canadian journal of cardiology
• 作者: Luo T;Liu H;Chen B;Liu H;Abdel-Latif A;Kitakaze M;Wang X;Wu Y;Chou D;Kim JK
• 通讯作者: Kim JK

Inducible Depletion of Calpain-2 Mitigates Abdominal Aortic Aneurysm in Mice.

• DOI: 10.1161/atvbaha.120.315546
• 发表时间: 2021-05-05
• 期刊: Arteriosclerosis, thrombosis, and vascular biology
• 作者: Muniappan L;Okuyama M;Javidan A;Thiagarajan D;Jiang W;Moorleghen JJ;Yang L;Balakrishnan A;Howatt DA;Uchida HA;Saido TC;Subramanian V
• 通讯作者: Subramanian V

De Novo Crohn's Disease Diagnosed in the Setting of Acute SARS-Cov-2 Infection Requiring Escalation of Infliximab Therapy Guided by Personalized Pharmacokinetics.

在急性 SARS-Cov-2 感染的情况下诊断出新发克罗恩病，需要在个性化药代动力学指导下升级英夫利昔单抗治疗。

• DOI: 10.26502/jppch.74050172
• 发表时间: 2024
• 期刊: Journal of pediatrics, perinatology and child health
• 作者: Romo,MartinVarea;Acharya,Kishor;Shelman,NathanR;Minar,Phillip;Denson,LeeA;Softic,Samir
• 通讯作者: Softic,Samir

Dennd5b-Deficient Mice are Resistant to PCSK9-Induced Hypercholesterolemia and Diet-Induced Hepatic Steatosis.

• DOI: 10.1016/j.jlr.2022.100296
• 发表时间: 2022-12
• 期刊: JOURNAL OF LIPID RESEARCH
• 影响因子: 6.5
• 作者: Mobilia, Maura;Whitus, Callie;Karakashian, Alexander;Lu, Hong S.;Daugherty, Alan;Gordon, Scott M.
• 通讯作者: Gordon, Scott M.